Press Releases NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX Other stock markets 01:43:43 2024-04-29 pm EDT			5-day change	1st Jan Change
12.9 ^USD	+2.06%		+8.62%	-13.93%

Apr. 24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
Apr. 10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	Apr. 24	BU
NovoCure : Corporate responsibility report	Apr. 22	PU
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	Apr. 08	AQ
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 05	BU
Novocure to Report First Quarter 2024 Financial Results	Apr. 01	BU
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 28	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	Mar. 28	AQ
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 27	BU
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO	Mar. 11	BU
NovoCure: Q4 Earnings Snapshot	Feb. 22	AQ
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	Feb. 22	BU
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	Jan. 18	BU
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma	Jan. 09	BU
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update	Jan. 08	BU
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer	Jan. 04	BU
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference	Dec. 27	BU
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability	Nov. 28	BU
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference	Nov. 21	BU
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting	Nov. 13	AQ
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting	Nov. 10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Press Releases

Filters